Biocon To Spin Off, List Biologics Unit In Future
Biocon plans to hive off and list its biologics vertical to meet capital needs and limit borrowings.
“We have clearly indicated that the biologics business will be spun off into a full-fledged subsidiary first, and then we will look at taking it to the market to raise further capital,” Kiran Mazumdar-Shaw, chairperson and managing director, said in an interview with BloombergQuint. “This is because Biocon is conservative in its debt-equity ratio. So we are not going to be highly leveraged.”
Mazumdar-Shaw said overseas opportunities were more “attractive” than the domestic market as local companies were indulging in price dumping.
The dynamics in India have to stabilise and that is when we will look at an India strategy.Kiran Mazumdar-Shaw, Chairperson and Managing Director, Biocon
Other Key Highlights:
On Current Biosimilar Markets:
- Strong acceptance for biosimilar of pegfilgrastim (used in post-chemotherapy treatment) in the U.S. augers well for other future launches.
- There will only be a handful of biosimilar players in a not-so-aggressive market due to investment and gestational timelines involved.
On Pricing Pressure From Originators Like Eli Lilly, Roche:
- The price cuts of originator companies are knee-jerk reactions.
- Orginators are cross-subsidising from protected markets and will not sustain for long once the protection is lost.
Insulin Glargine's U.S. Launch:
- We are on track for the U.S. launch; the market is expected to open up over the next 12 months.
Here's the full interview:
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
